Viking Therapeutics prices $550M public offering of 6.47M shares at $85/share

Viking Therapeutics, Inc.

Gross proceeds ~$550M from 6.47M shares at $85; underwriters have 30-day option for 970,650 additional shares.
Net proceeds to fund development of VK2809, VK2735, VK0214 programs and general corporate purposes.
Offering expected to close March 4, 2024; Morgan Stanley & Leerink Partners lead underwriters.
Directors and executive officers subject to 90-day lock-up until May 28, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Viking Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Leerink Partners LLC valued at approximately $550.0 million (effective 2024-02-28).

Action: entry
Agreement: underwriting
Counterparty: Morgan Stanley & Co. LLC and Leerink Partners LLC
Value: approximately $550.0 million
Effective: 2024-02-28

Exact text from the filing

On February 28, 2024, Viking Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC (the “Representatives”), as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 6,471,000 shares of the Company’s common stock (“Common Stock”).

View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

Viking Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-023838

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.